What Is Topical Steroid Withdrawal?

Topical steroid withdrawal is a skin condition that develops after a person stops using topical corticosteroids they have applied for an extended period, typically mid-to-high-potency formulations. The skin rebounds with intense redness, burning, and stinging that can be far worse than the original condition the steroids were meant to treat. Though dermatologists debated its existence for years, professional bodies in the United States, United Kingdom, Europe, and elsewhere now acknowledge it as a real adverse effect, even as the evidence base remains thinner than patients and clinicians would like.

What TSW Looks and Feels Like

The hallmark of topical steroid withdrawal is skin that turns red, burns, stings, and sometimes swells after the steroid cream or ointment is stopped. A systematic review published in the Journal of the American Academy of Dermatology found that erythema (widespread redness) was the most common sign, appearing in about 92% of reported cases, while burning and stinging were the most frequently reported symptoms, noted in roughly two-thirds of patients.¹ Peeling, cracking, and intense itching round out the picture, and many people experience sleep disturbances severe enough to significantly impair daily life.²

The same systematic review identified two broad subtypes. The papulopustular type features small raised bumps and pus-filled spots, while the erythematoedematous type presents with more pronounced redness, swelling, and burning sensations.³ In practice, the two subtypes can overlap, but the distinction matters because the swelling-dominant form tends to cause more pain and is sometimes confused with an allergic reaction or infection.

A complication that catches many people off guard is secondary bacterial infection. A large share of people going through TSW develop heavy colonization by Staphylococcus aureus, a bacterium that thrives on damaged, inflamed skin.⁴ Oozing, crusting, or skin that suddenly smells different can signal that bacteria have moved in, and addressing the infection becomes a separate medical problem layered on top of the withdrawal itself.

Who Gets TSW and Why

The systematic review’s demographics are striking: women accounted for about 81% of reported cases, and the face and genital area were involved in roughly 99% of them.⁵ Both of those patterns make pharmacological sense. Facial and genital skin is thinner and absorbs topical steroids more readily, making it more vulnerable to local changes from prolonged use. The gender skew may partly reflect that women are more likely to use steroid creams on the face for conditions like rosacea, perioral dermatitis, or cosmetic concerns, and may partly reflect reporting bias, since the condition was being documented largely through self-selected case reports at the time of the review.

The single strongest risk factor is duration and potency of use. TSW is described in the literature as a rebound effect that follows prolonged application of mid-to-high-potency topical corticosteroids.⁶ “Prolonged” is not precisely defined, which is itself part of the problem, but the systematic review described most cases as arising from long-term inappropriate use of potent formulations.⁷ Short courses of low-potency creams used as directed have not been convincingly linked to the syndrome.

That said, exactly who develops TSW and who does not remains poorly understood. Most people who use topical steroids long-term never experience withdrawal. The proportion of long-term users who go on to develop TSW is unknown because no large prospective studies have tracked it. This knowledge gap fuels much of the anxiety and debate surrounding the condition.

How the Medical Establishment Came Around

Topical corticosteroids have been a cornerstone of dermatological treatment since the 1950s. The rebound phenomenon was recognized about a decade after the molecule was introduced, yet for most of the intervening decades it received scant formal attention.⁸ For a long time, many dermatologists either downplayed the condition or attributed flare-ups after stopping steroids to the underlying disease reasserting itself rather than a withdrawal phenomenon.

That stance has shifted. The American Academy of Dermatology’s updated guidelines for managing atopic dermatitis now mention topical steroid addiction and topical steroid withdrawal as adverse side effects that can follow prolonged use of topical corticosteroids. The European atopic eczema guideline (EuroGuiDerm) similarly references “corticosteroid addiction syndrome.” In 2021, the United Kingdom’s Medicines and Healthcare products Regulatory Agency issued a drug safety update advising patients to seek help if they experience redness, burning, itching, or stinging upon stopping topical steroids. The National Eczema Society, the British Association of Dermatologists, the National Eczema Association in the United States, and DermNet in New Zealand have all issued statements recognizing the condition.⁹

Recognition, though, is not the same thing as a fully developed clinical framework. There are still no universally agreed-upon diagnostic criteria, no validated severity scoring system, and no randomized controlled trials specifically designed for TSW treatment. Researchers have described this as a genuine evidence gap, and it leaves clinicians relying on clinical experience and expert opinion more than most would prefer.

The Social Media Effect

If you search for topical steroid withdrawal online, you will find an enormous volume of content, especially on video platforms. An analysis of the top 100 TSW-related TikTok videos found that they collectively had over 200 million views, 45 million likes, and around 90,000 comments.¹⁰ That is a staggering amount of reach for a condition that, until recently, many dermatologists barely discussed.

The quality of that content is another story. The same analysis rated video quality using a validated scoring tool and found an average score of about 1.6 out of 5, which is quite poor. Every video in the sample was produced by a personal account rather than a healthcare professional, highlighting the near-total absence of dermatologists on the platform discussing this topic.¹¹ The researchers did note one silver lining: longer, higher-view-count videos tended to score higher on quality, suggesting that viewers were interacting more with the better material.

From the clinician’s side, a survey found that when doctors asked patients where they had learned about TSW, social media was the most common answer, cited by about 83% of those who volunteered a source. Internet searches came second at around 69%, and friends or family at 35%.¹² That means a large proportion of people raising TSW with their doctor have formed their understanding from content that is overwhelmingly patient-generated and often medically inaccurate. This does not mean these patients are wrong about what is happening to their skin, but it does mean the framework they are bringing to the appointment may include misconceptions mixed in with legitimate concerns.

When Patients and Doctors Talk Past Each Other

One of the most damaging dynamics around TSW is the breakdown in trust between patients and their doctors. Qualitative research exploring how patients talk about their steroid concerns found that when a doctor failed to acknowledge the patient’s views and instead emphasized the safety of topical corticosteroids, the patient often perceived the doctor as dismissive, and the therapeutic relationship suffered.¹³

This plays out in a predictable pattern. A patient experiencing worsening symptoms after stopping their steroid cream searches online, finds TSW content that matches their experience, and brings the concern to their dermatologist. If the dermatologist is skeptical of TSW, or simply unfamiliar with the recent recognition statements, they may reassure the patient that topical steroids are safe and suggest continuing treatment. From the patient’s perspective, the doctor just failed to acknowledge what they are living through. From the doctor’s perspective, they may genuinely believe the patient is experiencing a flare of their underlying eczema and worry that stopping treatment will make things worse. Both can be acting in good faith while ending up in conflict.

The practical fallout is that patients who feel dismissed are more likely to stop all treatment abruptly, avoid follow-up appointments, and rely entirely on peer support communities for guidance. That puts them at higher risk for complications like untreated infections, and it means they may be navigating a genuinely difficult medical situation without professional oversight. If you find yourself in this position, seeking out a dermatologist who is at least willing to discuss TSW as a possibility, even if they are cautious about it, is worth the effort.

Managing TSW

There is no single established treatment protocol for TSW, and a therapeutic review has noted that while many strategies show benefits, few are supported by rigorous clinical evidence.¹⁴ That said, a few approaches have started to gain traction among specialists.

The question of whether to stop topical steroids abruptly or taper gradually is one that patients understandably want a clear answer to. Management plans for TSW typically include gradual tapering of corticosteroid use before complete discontinuation, alongside supportive therapy for both physical and psychological symptoms.¹⁵ The rationale is intuitive: a slow step-down may blunt the severity of the rebound compared to going cold turkey. However, there are no head-to-head trials comparing abrupt cessation with various taper schedules, so the choice in practice comes down to the clinician’s judgment and the patient’s preference and tolerance.

For patients whose symptoms are severe enough to warrant systemic treatment, a Delphi consensus study among specialists reached agreement on dupilumab as a first-line systemic therapy for TSW.¹⁶ Dupilumab is a biologic medication already widely used for moderate-to-severe eczema, and the reasoning is that it can help control the inflammatory flare that accompanies withdrawal without reintroducing topical steroids. Access can be a barrier since dupilumab requires a prescription, is given by injection, and can be expensive depending on insurance coverage.

Supportive care fills in the gaps around any pharmacological strategy. Gentle emollients help with barrier repair and the cracking that accompanies withdrawal. Cool compresses and antihistamines can take the edge off itching, though many patients report that antihistamines do only so much for TSW-related itch, which seems to have a different quality than typical allergic itch. Managing secondary bacterial infections when they arise, typically with topical or oral antibiotics, is an important part of the process. And because sleep disturbance and psychological distress are so common, addressing those directly, whether through sleep hygiene changes, short-term sleep aids, or mental health support, matters more than it might initially seem.

TSW in Children

Although most of the literature on topical steroid withdrawal focuses on adults, the condition is not limited to them. A case series documented 10 children whose parents discontinued chronic topical corticosteroid use and who subsequently developed features typically associated with TSW in adults, including redness, burning, and flaring beyond what their original eczema had caused.¹⁷ The initial phase was difficult for the children and their families, but all of them ultimately improved. At the final review, four children had clear skin and another four had symptoms consistent with their original, pre-treatment atopic dermatitis rather than withdrawal.¹⁸

For parents, this is a fraught situation. Eczema in children is common and often distressing, and topical steroids are the standard first-line treatment for good reason: they work. The fear that treatment might lead to withdrawal can push parents toward avoiding steroids altogether, which can mean a child suffers through poorly controlled eczema unnecessarily. The pediatric cases described in the literature involved chronic, long-term use, not the short intermittent courses typically prescribed for childhood flare-ups. If your child has been prescribed a topical steroid for a brief course, the risk profile is very different from daily application over months or years.

What TSW Is Not

A common worry is that topical steroids applied to the skin suppress the body’s internal cortisol production, the way oral or injected steroids can. This concern is understandable but largely unfounded for typical use. A systematic review of studies measuring hypothalamic-pituitary-adrenal axis function in patients using topical steroids for plaque psoriasis found no evidence of clinically significant suppression, even in patients treating the scalp or those with extensive disease. When researchers used the Synacthen stimulation test, considered the gold standard for assessing adrenal function, results were always normal.¹⁹ Temporary dips in morning cortisol levels were occasionally seen, but these did not translate into the kind of adrenal insufficiency that accompanies withdrawal from systemic steroids.

This distinction matters because TSW appears to be a primarily local phenomenon: the skin itself changes during prolonged topical steroid exposure, involving alterations in blood vessel regulation, nitric oxide pathways, and local immune signaling. When the steroid is removed, those local systems rebound. It is not the same mechanism as someone tapering off prednisone pills after months of oral therapy, where the whole body’s cortisol axis has been suppressed and needs time to restart. The symptoms of TSW can be severe and debilitating, but they reflect what is happening in the skin rather than a systemic hormonal crisis.

Steroid Phobia and the Pendulum Problem

Awareness of TSW has had an unintended side effect: steroid phobia. As more people learn about withdrawal, some become so anxious about topical steroids that they refuse to use them at all, even when short-term use would be safe and beneficial. Dermatologists have noted this as a growing clinical challenge. A patient with a severe eczema flare who avoids a two-week course of a mild steroid cream because they fear addiction is making a decision based on risk perception that does not match the evidence. The cases documented in TSW literature overwhelmingly involve long-term, often daily use of moderate-to-potent formulations, not brief courses of mild ones.

The recognition of TSW by professional bodies was meant to validate patients’ experiences and improve care, not to imply that all topical steroid use is dangerous. There is an awkward tension between these goals. Telling patients that TSW is real but also that topical steroids remain a safe and effective treatment when used appropriately requires nuance, and nuance does not travel well through social media algorithms. A 60-second TikTok video of someone’s inflamed skin set to dramatic music conveys a visceral warning that no amount of measured clinical reassurance can easily counter.

For people trying to make sense of their own situation, the most useful framing is probably this: if you have been using topical steroids intermittently, for short periods, on your doctor’s guidance, you are in a very different risk category from someone who has been applying a potent steroid to their face daily for years. The two situations are not comparable, even though the same class of medication is involved. And if you are concerned about dependency, raising that concern with your prescriber early, rather than stopping abruptly on your own, gives you the best chance of a good outcome regardless of whether TSW turns out to be part of your picture.